NASDAQ:SAVA It seems to be more of a technical play to me than just news based. What do you all think?
Short attack or legitimate fraud ? We've seen these claims before go both ways , High Risk High Reward here IMO . Entered credit spread 45/40P for 10/15 given the buyers stepped in at the 200MA very strongly. Wouldn't be surprised if this was trading back in the 100s or 20s by next week :) 99% of gaps get filled, just a matter of when ...
Idea for Cassava Sciences (SAVA): - Decoded: PVVol: - H&S pattern, Distribution UTAD with Exhaustion gap (Price). - High Volume sell (Volume). - > 5x ATR (Vol). - 4.236 Fib. - ML Diamond. PT: 36 Time: By Sept 8, but add 0.3 bars margin (Sept 27) SL: 2.4N~ 128.38 GLHF - DPT
$SAVA (Cassava Sciences) saw an insane rally in 2021 from $7 to $145 on the hopes that its groundbreaking Alzheimer's treatment will yield promising results never before seen in the history of the disease. Currently there are no Alzheimer's modifying therapies on the market and if the data surrounding Cassava's main drug, simufilam, is accurate then it could be...
It's interesting to see what happens after plotting out fib lines sometimes. SAVA , for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some...
WATCHING $SAVA for Entry Target @ 97.43 ———— I will repost when it get’s closer (or if I take a position)if it goes that way and if it makes higher highs I’ll repost with new entry.
Symbol: NASDAQ:SAVA Indicators Lag RSI My Opinion: Bullish Comments: Stock is looking bullish and has just been massively trending upwards!
About the Tickers: Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an...
ESPERAR AL RECHAZO DE LAS MEDIAS PARA ENTRAR.
This is a nice example of how following who's involved can lead to excellent opportunities. Just look at $SAVA. In the Christmas months of 2019, multiple insiders were seen purchasing $100's of thousands worth of shares immediately before the share price skyrocketed several hundred percent. Fast forward 13 months later, and the price broke $100.. Still, many...
Chart reviews of the 4 stocks I'm watching. Also going over my trades for today.
#swing #tradeidea
10.63 ENTRY PRICE 9.57 10% STOP LOSS 11.16 5% TARGET 11.69 10% TARGET RSI above + 50 & 70 levels with a steep incline. Volume is at 100% +++. 200 sma on an incline showing uptrend. Price stayed above 50 sma with a brief bearish pullback. Current Price is a strong large body bullish reversal candle.
Looks like SAVA is going to move up - good time to get in at 8.26 - 8.28. NASDAQ:SAVA
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. SHORT INTEREST 1.64M 08/30/19 P/E Current -2.07 P/E Ratio...
The Stated Value of the Preferred Shares is $20.00 per unit, and the annual interest payment, which is to be paid out in quarterly installments, is 8%". That translates into $2,000,000 worth of shares per year. In regards to the warrants, if we multiply 7.41 by 1 250 000, we get 9,262,500 common shares, and it says that the warrants are exercisible...